Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE